Loading organizations...
Key people at BioMotiv.
BioMotiv functions as a pharmaceutical accelerator, specializing in advancing early-stage biomedical discoveries into therapeutic candidates. It supplies crucial drug development expertise, strategic capital, and industry partnerships to propel promising research forward. The company’s operational framework streamlines the complex process of translating scientific insights into clinical potential.
Founded in 2012 as a mission-aligned partner of the Harrington Discovery Institute, BioMotiv originated from The Harrington Project for Discovery & Development. The founding insight addressed the critical gap between academic scientific breakthroughs and their development into accessible medicines. This initiative leverages the significant resources and medical expertise of University Hospitals.
The company primarily supports academic innovators and research institutions with discoveries needing professional development to achieve market potential. BioMotiv’s vision focuses on accelerating high-potential scientific findings into tangible, life-improving medicines. It aims to address significant unmet medical needs through its dedicated portfolio companies.
Key people at BioMotiv.
BioMotiv has 3 tracked investments across 2 companies. The latest tracked deal is $53.0M Series B in Amphista Therapeutics in March 2021.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Mar 1, 2021 | Amphista Therapeutics | $53.0M Series B | Forbion | Therese Liechtenstein, Novartis Venture Fund, Omega Funds, Pfizer Venture Investments, Vincent Brichard, Advent Life Sciences, ELI Lilly And Company, Florian Müllershausen |
| Jan 5, 2021 | Aro Biotherapeutics | $88.0M Series A | Kevin Raidy, Shaan Gandhi | BVF Partners, HealthCap, Ionis Pharmaceuticals, Johnson & Johnson Innovation, Ridgeback Capital Investments |
| Dec 11, 2018 | Aro Biotherapeutics | $13.0M Other Equity | Biomotiv, Johnson & Johnson Innovation | — |
